For the past 10 years, immunotherapy has emerged as a promising approach to combat advanced stages of cancers. The ability of immune system to detect foreign matters and produce proteins (antibodies) against them is one of the essential means by which the body protect itself against diseases. In a similar vein, delivering substantial amount of antibodies targeting the tumor complex has been considered as a potentially effective approach to treat cancer. Monoclonal antibody (mAb) have demonstrated to be a useful addition to the armamentarium for many types of cancer. Pertuzumab, panitumumab, trastuzumab, and cetuximab, mAbs that are directly binding to the receptors of the epidermal growth factor family, result in the diminished function of subsequent signaling pathways. 1) In addition to signaling interruption, some of these mAbs can also activate antibody-dependent cellular cytotoxicity (ADCC) to cancer cells. 2)